Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Inclusion Criteria: * Age \>= 18 years * Note: Because no dosing or adverse event data are currently available on the use of talimogene laherparepvec (T-VEC) in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials * Newly diagnosed and a histopathologically confirmed potentially resectable soft tissue sarcoma of the extremity or trunk of the following subtypes: * Cohort 1: liposarcoma (excluding myxoid liposarcoma) * Cohort 2: leiomyosarcoma * Cohort 3: undifferentiated pleomorphic sarcoma (UPS) (malignant fibrous histiosarcoma \[MFH\]) * NOTE: If local pathology report is suggestive of or suspicious for UPS, study chair and study pathologists may review for eligibility determination. * NOTE: Sites permissible for biopsy include * Extremities: upper (including shoulder) and lower (including hip) * Trunk: Body wall * Patients must have a histologically determined grade 2 or 3 tumor by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) sarcoma grading system * Patients must have localized disease with a primary tumor \> 5 cm by MRI or computed tomography (CT) scan * Patients must have a primary tumor that is determined by multidisciplinary team (medical oncology, orthopedic/surgical oncology, and radiation oncology) to require radiation therapy for optimal management prior to surgical resection * Patients must have a sarcoma in the extremity or trunk in location, which is accessi…